TY - JOUR
T1 - Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection
T2 - Does Site of Metastases Matter?
AU - on behalf of the BIG-RENAPE Working Group
AU - Passot, Guillaume
AU - Kim, Bradford J.
AU - Glehen, Olivier
AU - Mehran, Reza J.
AU - Kopetz, Scott E.
AU - Goere, Diane
AU - Overman, Michael J.
AU - Pocard, Marc
AU - Marchal, Frédéric
AU - Conrad, Claudius
AU - Aloia, Thomas A.
AU - Vauthey, Jean Nicolas
AU - Chun, Yun Shin
AU - Abba, Julio
AU - Abboud, Karine
AU - Alyami, Mohammad
AU - Arvieux, Catherine
AU - Asnacios, Amani
AU - Averous, Gerlinde
AU - Bakrin, Naoual
AU - Bardier, Armelle
AU - Rejeb, Houda Ben
AU - Bereder, Jean Marc
AU - Bernard, Jean Louis
AU - Bibeau, Frédéric
AU - Bonnefoy, Isabelle
AU - Borg, Christophe
AU - Boschetti, Gilles
AU - Bouarioua, Nadia
AU - Bouche, Olivier
AU - Bouzard, Dominique
AU - Brigand, Cécile
AU - Cacheux, Wulfran
AU - Capitain, Olivier
AU - Carrère, Sébastien
AU - Carretier, Michel
AU - Castel, Benjamin
AU - Chauvenet, Marion
AU - Chevallier, Anne
AU - Coffin, Benoît
AU - Costan, Cristina
AU - Cotte, Eddy
AU - Courvoisier, Thomas
AU - Dahan, Laetitia
AU - Dartigues, Peggy
AU - De Chaisemartin, Cécile
AU - Dechelotte, Pierre
AU - Deguelte-Lardière, Sophie
AU - Delpero, Jean Robert
AU - Del Grande, Jean
N1 - Publisher Copyright:
© 2017, Society of Surgical Oncology.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background: RAS mutation status is an important prognostic factor after resection of liver metastases (LiM) from colorectal cancer (CRC). The prognostic significance of RAS after resection of lung (LuM) and peritoneal (PM) metastases from CRC is unknown. Methods: Between 2005 and 2014, all consecutive patients with known RAS status who underwent potentially curative resection for LiM, LuM, or PM were evaluated. Results: A total of 720 patients with known RAS status underwent resection of LiM (n = 468), LuM (n = 102), and PM (n = 150). RAS mutations were identified in 63 and 58% of patients with LuM and PM, respectively, compared with 41% of patients with LiM (p < 0.001). Five-year overall survival (OS) after resection of PM was 45%, compared with 52% after resection of LiM (p = 0.018) and 64% after resection of LuM (p = 0.005). RAS mutations were associated with significantly worse OS after resection of LiM (p < 0.001), but did not affect OS among patients undergoing resection of LuM (p = 0.41) and PM (p = 0.65). Conclusions: RAS mutations are more prevalent among patients undergoing resection of LuM and PM than LiM but do not affect survival after lung and peritoneal metastasectomy, as they do after hepatectomy. These results suggest that the prognostic significance of RAS mutations after resection of metastatic CRC depends on the specific site of metastases.
AB - Background: RAS mutation status is an important prognostic factor after resection of liver metastases (LiM) from colorectal cancer (CRC). The prognostic significance of RAS after resection of lung (LuM) and peritoneal (PM) metastases from CRC is unknown. Methods: Between 2005 and 2014, all consecutive patients with known RAS status who underwent potentially curative resection for LiM, LuM, or PM were evaluated. Results: A total of 720 patients with known RAS status underwent resection of LiM (n = 468), LuM (n = 102), and PM (n = 150). RAS mutations were identified in 63 and 58% of patients with LuM and PM, respectively, compared with 41% of patients with LiM (p < 0.001). Five-year overall survival (OS) after resection of PM was 45%, compared with 52% after resection of LiM (p = 0.018) and 64% after resection of LuM (p = 0.005). RAS mutations were associated with significantly worse OS after resection of LiM (p < 0.001), but did not affect OS among patients undergoing resection of LuM (p = 0.41) and PM (p = 0.65). Conclusions: RAS mutations are more prevalent among patients undergoing resection of LuM and PM than LiM but do not affect survival after lung and peritoneal metastasectomy, as they do after hepatectomy. These results suggest that the prognostic significance of RAS mutations after resection of metastatic CRC depends on the specific site of metastases.
UR - http://www.scopus.com/inward/record.url?scp=85032221573&partnerID=8YFLogxK
U2 - 10.1245/s10434-017-6141-7
DO - 10.1245/s10434-017-6141-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 29071660
AN - SCOPUS:85032221573
SN - 1068-9265
VL - 25
SP - 179
EP - 187
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 1
ER -
